As Freenome’s Chief Executive Officer, Aaron directs the company’s strategy and operational execution to ensure our overall success and growth.    

Aaron joins Freenome most recently from REALM IDx, Inc., where he served as CEO and president for nearly four years, overseeing its subsidiaries Ambry Genetics, Invicro and Konica Minolta REALM-Japan. He led the acquisition of Ambry by Konica Minolta for $1 billion in 2017.

From 2016 to 2021, Aaron led Ambry Genetics as CEO and transformed the company into one of the largest hereditary cancer testing labs in the world by launching tests with best-in-class diagnostic yield and unique population health tools to identify patients at risk for cancer. He joined Ambry in 2008 as an R&D scientist and would later become its chief scientific officer. 

Aaron did his genetics Ph.D. training at the Sidney Kimmel Cancer Center at Thomas Jefferson University and The Johns Hopkins University School of Medicine, and he holds a Bachelor of Science in Biology from Franklin & Marshall College.